

A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

10/12/2017

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [4-3.50]	(0)	(0)	(2) 50.00%	(2) 50.00%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [4-3.50]	(0)	(0)	(2) 50.00%	(2) 50.00%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [4-3.50]	(0)	(0)	(2) 50.00%	(2) 50.00%

2. Please elaborate on your previous answers. (2)

Attending this course helped me understand association between renal disease and HCV infection, and effective therapy for previously difficult to treat population.

Excellent program and presenter

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and /or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Paul Pockros, MD [2-4.00]	(0)	(0)	(0)	(2)100%

4. Please elaborate on your previous answers. (3)

Carrie Frenette is an excellent speaker. She's entertaining and involves those in attendance. You know it's a good talk when the audience is asking questions and are

engaged.

Dr. Frenette's presentation was excellent.

Dr. Frenette presented the program

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (2)

glecaprevir/pibrentasvir is an effective therapy.

New knowledge

6. How certain are you that you will implement this change?

(2)

Very Certain ⁽¹⁻
50.00%)

Certain ⁽¹⁻
50.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (2)

hepatitis B, NASH.

Endometriosis & Uterine Fibroids

8. Were the patient recommendations based on acceptable practices in medicine?

(2)

Yes ⁽²⁻
100.00%)

10. Do you think the presentation was without commercial bias?

(2)

Yes ⁽²⁻
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

None.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

1/30/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [7-3.71]	(0)	(0)	(2) 28.57%	(5) 71.43%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [6-3.83]	(0)	(0)	(1) 16.67%	(5) 83.33%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [6-3.50]	(0)	(1) 16.67%	(1) 16.67%	(4) 66.67%

2. Please elaborate on your previous answers. (5)

interesting latest research, important to understand disease trajectory for prognosis

recent option of meds is fantastic

Excellent review

i am now aware of the relationship of Hep C and end stage renal disease

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Ira Jacobson, MD [3-4.00]	(0)	(0)	(0)	(3)100%
Cathleen Frenette, MD [1-4.00]	(0)	(0)	(0)	(1)100%
Hugo Vargas, MD [1-4.00]	(0)	(0)	(0)	(1)100%

Norman L. Sussman, MD [3-4.00]	(0)	(0)	(0)	(3)100%
Dr. Pyrsopoulos [1-4.00]	(0)	(0)	(0)	(1)100%

4. Please elaborate on your previous answers. (3)

well presented

excellent lecture

speakers were very knowledgeable.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (5)

none- I work in palliative care and don't prescribe these meds or enroll in trials

more thorough evaluation of Hep c pos pts

major take away is ongoing screening in treated Hep C patients.

no special changes. Will refer to a specialist

6. How certain are you that you will implement this change?

(6)

Certain (2-
33.33%)

Very Certain (2-
33.33%)

N/A (2-
33.33%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (4)

new advanced that impact on prognosis, disease trajectory

management of Hep B pos patients

ability for uninsured patients to get care

8. Were the patient recommendations based on acceptable practices in medicine?

(6)

Yes (6-
100.00%)

10. Do you think the presentation was without commercial bias?

(6)

Yes (6-
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

enjoyed the talk very much

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

2/1/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [15-3.93]	(0)	(0)	(1) 6.67%	(14) 93.33%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [15-3.60]	(0)	(0)	(6) 40.00%	(9) 60.00%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [15-3.53]	(0)	(1) 6.67%	(5) 33.33%	(9) 60.00%

2. Please elaborate on your previous answers. (10)

I had very little previous knowledge on this topic before this presentation.

knowing now that hep c is curable

hep c with ESRD can be treated

I had a great time Listening Dr. Gish. It helped me understand what the correlation between hepatic and kidney system and how to treat positive Hep C before kidney transplant if needed one is.

It was really good education session

it enhanced my knowledge regarding Hepatitis C in relation to HD

Our organization does not have the tools and physician buy in.

I had old "fashioned" knowledge on the cures for hepatitis C or the type of patients that can acquire hepatitis

This was a very informative lecture.

Learned about the "new" knowledge and treatments for Hep C

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Ira Jacobson, MD [3-2.67]	(1) 33.33%	(0)	(1) 33.33%	(1) 33.33%
Robert Gish, MD [15-3.93]	(0)	(0)	(1) 6.67%	(14) 93.33%
Paul Pockros, MD [3-3.67]	(0)	(0)	(1) 33.33%	(2) 66.67%
Cathleen Frenette, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Hugo Vargas, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Norman L. Sussman, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Dr. Pyrsopoulos [1-3.00]	(0)	(0)	(1)100%	(0)

4. Please elaborate on your previous answers. (11)

Dr. Gish was an excellent presenter.

a new approach to tx of hep c

hep c can be treated

Dr. Gish is a great speaker. His presentation was evident, concise and to the point.

Good Learning

informative

Dr. Gish expressed the team approach in a confident manner. His explanations were meaning and appropriate to my RN scope

Speaker was only Dr Gish. Accidently clicked on Ira.

The speaker delivery of the information was very effective.

Very knowledgable

Very good instructor

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (14)

n/a

monitoring labs

new meds,labs to monitor

Screening for Hep C on patients who meet criteria

Better understanding of the treatment for all with Hepatitis C

Providing more education to baby boomer regarding Hep C screening and encouraging the patient to seek appropriate treatment.

none

more handouts

Promotion of the tool used in lieu of the liver biopsy technique

Increased knowledge but do not have a clinical practice

Yes

Better awareness of opportunities for kidney transplant
ability to refer to liver centers or hepatologists

6. How certain are you that you will implement this change?

(13)

N/A ⁽⁴⁻
30.77%)

Certain ⁽³⁻
23.08%)

Very Certain ⁽⁵⁻
38.46%)

Maybe ⁽¹⁻
7.69%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (9)

CVA, heart disease, Parkinson's etc.

contraindications of new meds

lupus

Medication accessibility and coverage

GI issues, Cirrhosis

Liver dialysis if there is any

Hypoglycemic events, Sepsis, Massive blood transfusion issues, Non-invasive cardiac monitoring and cardiac shock

not sure

General liver disease in cirrhosis and treatments

8. Were the patient recommendations based on acceptable practices in medicine?

(14)

Yes ⁽¹³⁻
92.86%)

No ⁽¹⁻
7.14%)

9. If you answered No on the question above, please explain which recommendation(s) were not based on acceptable practices in medicine? (2)

n/a

Utilizing an infected HCV donor kidney. Is there any liability?

10. Do you think the presentation was without commercial bias?

(14)

Yes (14-
100.00%)

11. If you answered No on the above question, please list the topics that were biased? (1)

n/a

12. Please provide any additional comments you may have about this educational activity. (8)

n/a

technology and science are advancing more and not so invasive for pt's safety,all we need is funding

technology is great and not invasive for pt's safety esp with liver cirrhosis,ESRD

It was great presentation. I have taken care of patient with Hep C and kidney failure. But this class has totally changed my perception to view hep C and kidney failure patient in different way meaning more hopeful with new medications.

Good learning session

none so far

Thank you for the sponsorship and thank you to Dr. Gish. Excellent presentation. It is very often that clinicians promote the cure for HCV.

none

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

2/28/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [6-4.00]	(0)	(0)	(0)	(6)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [6-3.83]	(0)	(0)	(1) 16.67%	(5) 83.33%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [6-3.33]	(0)	(2) 33.33%	(0)	(4) 66.67%

2. Please elaborate on your previous answers. (6)

I was not aware of the time frame it took for treatment to be a cure for Hep C.

Excellent information

I am retired and do limited consulting work.

Never was aware of the advances in Rx of HCV or the systemic manifestations of HCV

Retired. Occasionally asked to offer an opinion on a subject.

Management of patients with renal failure and Hep C will be more aggressive.

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor =

1, Excellent = 4)

	Poor	Fair	Good	Excellent
Robert Gish, MD [6-4.00]	(0)	(0)	(0)	(6)100%

4. Please elaborate on your previous answers. (6)

Dr. Gish was my speaker. None of the others were in attendance

Extremely knowledgeable

Don't recognize the other names

Dr Gish was the only presenter

Don't recognize other names

Authoritative, fully knowledgeable, practicable common type familiar case presentations.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (6)

Start to utilize Hep C drugs with my few Hep C patients

Aware of new protocols

N/A

Test all lymphoma patients for HCV

N/A

Will transplant renal failure patients with HepC planning to treat the HepC as well.

6. How certain are you that you will implement this change?

(6)

Very Certain (3-
50.00%)

Certain (1-
16.67%)

N/A (2-
33.33%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (4)

STATUS OF PRECISE MEDICINE

Lymphoma advances

N/A

Methods and training for first assistant surgeons to prophylax primary surgeons to prevent activity that could precipitate events that might create operative events leading to law suites.

8. Were the patient recommendations based on acceptable practices in medicine?

(6)

Yes (6-
100.00%)

10. Do you think the presentation was without commercial bias?

(6)

Yes ⁽⁶⁻
100.00%)

12. Please provide any additional comments you may have about this educational activity. (3)

APPRECIATE THE PRESENTATION

Appreciate your involvement in continuing education.

No handouts provided for slides or reprints to take home.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

3 / 6 / 2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [1-4.00]	(0)	(0)	(0)	(1)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [1-4.00]	(0)	(0)	(0)	(1)100%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [1-4.00]	(0)	(0)	(0)	(1)100%

2. Please elaborate on your previous answers. (1)

Educational program

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Norman L. Sussman, MD [1-4.00]	(0)	(0)	(0)	(1)100%

4. Please elaborate on your previous answers. (1)

Very good coverage of the topic

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (1)

More treatment of hepatitis C in this population.

6. How certain are you that you will implement this change?

(1)

Certain ⁽¹⁻
100.00%)

8. Were the patient recommendations based on acceptable practices in medicine?

(1)

Yes ⁽¹⁻
100.00%)

10. Do you think the presentation was without commercial bias?

(1)

Yes ⁽¹⁻
100.00%)

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

3/20/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [8-3.13]	(1) 12.50%	(0)	(4) 50.00%	(3) 37.50%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [8-3.25]	(0)	(1) 12.50%	(4) 50.00%	(3) 37.50%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [8-3.25]	(0)	(1) 12.50%	(4) 50.00%	(3) 37.50%

2. Please elaborate on your previous answers. (1) limited number of Pts with this presentation

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Hugo Vargas, MD [8-3.75]	(0)	(0)	(2) 25.00%	(6) 75.00%

4. Please elaborate on your previous answers. (2)
well informed and well spoken.

did an excellent job elaborating on slide deck

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (7)

Await info on safety of sof containing regimens in HCV ESRD. Continue to use Mavyret and Zepatier. Consider deferring treatment until after kidney transplant in eligible patients.

new meds to treat pt with Hep C

Treat HCV infected renal patients

Change in referral pattern

identifying degrees of renal insufficiency and drugs to treat hep C

increased awareness

Better understanding of the issues involved

6. How certain are you that you will implement this change?

(8)

Certain (6-
75.00%)

Very Certain (2-
25.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)

NASH

8. Were the patient recommendations based on acceptable practices in medicine?

(6)

Yes (6-
100.00%)

9. If you answered No on the question above, please explain which recommendation(s) were not based on acceptable practices in medicine? (1)

Managing hepatic encephalopathy

10. Do you think the presentation was without commercial bias?

(8)

Yes (8-
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

Extremely useful and timely

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

3/28/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [3-2.67]	(1) 33.33%	(0)	(1) 33.33%	(1) 33.33%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [3-2.67]	(1) 33.33%	(0)	(1) 33.33%	(1) 33.33%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [3-2.67]	(1) 33.33%	(0)	(1) 33.33%	(1) 33.33%

2. Please elaborate on your previous answers. (2)

N/a

We can begin to implement and change coordination of care in patient with ESRD with patient with Hep C seen in office.

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Ira Jacobson, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Robert Gish, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Paul Pockros, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Cathleen Frenette, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Hugo Vargas, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Norman L. Sussman, MD [1-3.00]	(0)	(0)	(1)100%	(0)
Dr. Pyrsopoulos [3-3.67]	(0)	(0)	(1) 33.33%	(2) 66.67%

4. Please elaborate on your previous answers. (1)

Engaged in audience participation and encouraged questions

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (2)

Selecting population to treat with esrd

New protocols on treatment guidelines, medications and imaging studies

6. How certain are you that you will implement this change?

(2)

Maybe (1-
50.00%)

Certain (1-
50.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)

Fatty liver

8. Were the patient recommendations based on acceptable practices in medicine?

(3)

Yes (3-
100.00%)

10. Do you think the presentation was without commercial bias?

(3)

Yes (3-
100.00%)

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

NO Evaluation Responses have been submitted for this form

A Team-based Approach to Treating HCV in Patients with End-Stage Renal Disease

4/18/2018



A Team-based Approach to Treating HCV in Patients with End- Stage Renal Disease

5/2/2018

This activity was created to address the professional practice gaps listed below:

- Identifying the strong and likely causal association between chronic hepatitis C virus and kidney disease and utilizing current diagnosis and treatment options to treat this co-morbidity.
- Diagnosing liver disease in their kidney disease patients allowing for a broader array of treatment regimes.
- Identifying current clinical trials that support new agents for late stage kidney disease patients with HCV.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree		Strongly Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [1-4.00]	(0)	(0)	(0)	(1)100%

Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [1-4.00] (0) (0) (0) (1)100%

Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [1-4.00] (0) (0) (0) (1)100%

2. Please elaborate on your previous answers. (1)
New approaches, therapies, timing of therapy, and medication for HCV/ESRD

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

Poor	Fair	Good	Excellent
------	------	------	-----------

4. Please elaborate on your previous answers. (1)
None of the above named physicians were speakers. Dr. Ram Bhamidimarri was excellent

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (1)
timing of therapy and newer medication protocols

6. How certain are you that you will implement this change?

(1)

Very Certain (1-100.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)
The tereapy of Hep C is rapidly changing and will always need updates

8. Were the patient recommendations based on acceptable practices in medicine?

(1)

Yes (1-100.00%)

10. Do you think the presentation was without commercial bias?

(1)

Yes (1-100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)
Excellet program, I recommend it to all community gastroenterologists/hepatologists

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very

much.